Bain Capital Invests up to $300M in Cardurion Pharmaceuticals
October 27, 2021
Cardurion Pharmaceuticals, a clinical‑stage biotechnology company focused on cardiovascular therapeutics, received a private investment of up to $300 million from Bain Capital Life Sciences and Bain Capital Private Equity to advance its PDE9 and CaMKII inhibitor programs and to scale the business. The funding will support a major Phase 2 heart‑failure trial, initiation of first‑in‑human studies, and company growth; Bain Capital will also join Cardurion’s board alongside existing investors Takeda Pharmaceuticals and Polaris Partners.
- Targets
- Cardurion Pharmaceuticals
- Industry
- Biotechnology
- Location
- Massachusetts, United States
- Transaction Type
- Growth capital
Explore More
Related Acquisitions
-
Bain Capital Takes Strategic Growth Investment Stake in Duravent Group
March 18, 2026
Industrial Services
Duravent Group, a venting and air quality solutions provider for HVAC professionals, announced it secured a significant strategic growth investment from Bain Capital. Bain will partner with Duravent’s leadership and existing investor Egeria to accelerate growth, deepen category leadership, and expand the platform through organic investment and strategic acquisitions.
-
Bain Capital and Bristol Myers Squibb Launch NewCo with $300M to Develop Immunology Therapies
July 31, 2025
Biotechnology
Bristol Myers Squibb (BMS) and Bain Capital have created a new independent biopharmaceutical company (NewCo) to advance five licensed immunology assets, with Bain Capital committing $300 million and support from the Canada Pension Plan Investment Board. BMS licensed three clinical-stage and two Phase 1-ready programs to NewCo and will retain nearly a 20% equity stake while joining the new company's board.
-
Bain Capital and Kohlberg Lead Strategic Investment in PCI Pharma Services
July 14, 2025
Healthcare Services
PCI Pharma Services, a Philadelphia-based contract development and manufacturing organization (CDMO), received a strategic growth investment co-led by Bain Capital and existing lead investor Kohlberg, with significant reinvestment from Mubadala and a continuing minority stake from Partners Group. The capital will be used to accelerate PCI's organic and inorganic growth, expand sterile fill-finish and specialized manufacturing capacity, and broaden its geographic footprint to support biopharma customers and U.S. pharmaceutical supply-chain resilience.
-
Bain Capital Life Sciences Leads $200M Growth Investment in Serán Bioscience
September 17, 2024
Pharmaceuticals
Bain Capital Life Sciences led a strategic growth investment of more than $200 million in Serán Bioscience, with existing investor Vivo Capital remaining a key shareholder. The capital will fund a new commercial-scale manufacturing campus in Bend, Oregon, expanding Serán's development, analytical and commercial manufacturing capabilities across multiple drug delivery modalities.
-
Novo Nordisk to Acquire Cardior Pharmaceuticals for Up to €1.025 Billion
March 25, 2024
Biotechnology
Novo Nordisk agreed to acquire Cardior Pharmaceuticals for up to €1.025 billion, consisting of an upfront payment plus additional milestone payments tied to development and commercial progress. The deal is expected to strengthen Novo Nordisk’s cardiovascular pipeline, centered on Cardior’s lead candidate CDR132L in phase 2 heart failure trials.
-
Bain Capital Private Equity Takes Majority Stake in InnovaCare Health
November 19, 2021
Healthcare Services
Bain Capital Private Equity has signed a definitive agreement to acquire a majority stake in InnovaCare Health, a regional leader in integrated and value-based healthcare services. The investment will support InnovaCare's national expansion and accelerate growth of its physician-led, value-based care model; Summit Partners will remain an equity holder and management will retain significant ownership.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.